Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy

The Food and Drug Administration said Monday it will perform a speedy review of Sarepta Therapeutics' (SRPT) muscular dystrophy gene therapy, and SRPT stock jumped.X Sarepta filed for approval based on three clinical studies of the gene therapy, SRP-9001. But one study, called Embark, is still…#sareptatherapeutics #sarepta #genetherapy #srpt #gene #sareptagene #therapeutics #therapy #fda #embark
Source: Reuters: Health - Category: Consumer Health News Source Type: news